Opinion|Videos|August 9, 2024
Real-World Evidence and Emerging Therapies in Lower-Risk MDS: Insights from EHA 2024
Key opinion leaders (KOLs) examine real-world evidence and draw on their clinical experiences to inform their practice, discussing real-world dose escalations and key insights gained from practical application.
Advertisement
Episodes in this series
- Focusing on real-world evidence (RWE), how do outcomes compare what’s seen in practice and how does that impact your choice of therapy?
- Real-world dose escalation and outcomes of luspatercept across all LOTs (
Patel K, et al. EHA 2024. Abstract P768. )
- Real-world dose escalation and outcomes of luspatercept across all LOTs (
- IMerge study, PROs in heavily pre-treated patients with LR-MDS:
Sekeres MA, et al. Blood. 2023; 142 (suppl 1):6479. - Real World Data Replicates Medalist Study Results (
Komrokji RS et al. Blood 2022 )
- Can each of you share any key takeaways or additional data updates surrounding lower-risk MDS presented at EHA 2024? (if time permits)
- Let’s discuss novel agents and/or combination strategies in LR-MDS through ongoing research that may shape the future treatment landscape.
- Luspatercept plus erythropoietin in LR-MDS:
Jonasova A, et al. EHA 2024. Abstract P1886 . - Luspatercept plus ESA combinations in LR-MDS:
Komrokji RS, et al. Blood Adv. 2023. - Ph 2 study, elritercept (KER-050):
Díez Campelo M, et al. EHA 2024. Abstract S183 .
- Luspatercept plus erythropoietin in LR-MDS:
Advertisement
Related to this article
Experts break down key melanoma data and trends from the 2026 ESMO Congress.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Experts break down key kidney cancer data and trends from the 2026 ESMO Congress.
Durvalumab plus BCG is now an approved first-line option for high-risk NMIBC, but better BCG delivery and biomarker-guided selection should shape its use.
The FDA has approved amivantamab and hyaluronidase-lpuj for metastatic head and neck squamous cell carcinoma.
A UCLA-led study suggests routine mammograms or other breast imaging may not benefit women after double mastectomy for DCIS.
Experts break down key gynecologic cancer data and trends from the 2026 ESMO Congress.
Are we ready to “take that fork in the road” and move palliative/supportive care into routine cancer care?
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Amivantamab and Hyaluronidase for Metastatic HNSCC
2
BCG Optimization Becomes a Priority as Durvalumab Gains a Role in High-Risk NMIBC
3
Dr Cai on the Rationale for Evaluating Rocbrutinib Plus R-CHOP in Non-GCB DLBCL and MCL
4
Dr Skoulidis on Divarasib vs Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC
5